The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)
| Status: | Enrolling by invitation |
|---|---|
| Conditions: | Neurology, Hematology |
| Therapuetic Areas: | Hematology, Neurology |
| Healthy: | No |
| Age Range: | 18 - 85 |
| Updated: | 3/14/2019 |
| Start Date: | July 2015 |
| End Date: | August 2022 |
A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients With Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Patisiran Clinical Study
The purpose of this study is to evaluate the safety and efficacy of long-term dosing with
ALN-TTR02 (patisiran) in patients with transthyretin (TTR) mediated amyloidosis (ATTR).
ALN-TTR02 (patisiran) in patients with transthyretin (TTR) mediated amyloidosis (ATTR).
Inclusion Criteria:
- Have completed a patisiran study (i.e., completed the last efficacy visit in the
parent study) and, in the opinion of the investigator, tolerated study drug
- Be willing and able to comply with the protocol-required visit schedule and visit
requirements and provide written informed consent
Exclusion Criteria:
- Any new or uncontrolled condition that could make the patient unsuitable for
participation
We found this trial at
14
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials